Malin (LTS:0Y71) Change In Receivables : €0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Malin Change In Receivables?

Malin's change in receivables for the quarter that ended in Dec. 2024 was €0.00 Mil. It means Malin's Accounts Receivable stayed the same from Jun. 2024 to Dec. 2024 .

Malin's change in receivables for the fiscal year that ended in Dec. 2024 was €-0.30 Mil. It means Malin's Accounts Receivable increased by €0.30 Mil from Dec. 2023 to Dec. 2024 .

Malin's Accounts Receivable for the quarter that ended in Dec. 2024 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Malin's liquidation value for the six months ended in Dec. 2024 was €56.80 Mil.

Malin Change In Receivables Historical Data

The historical data trend for Malin's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Malin Change In Receivables Chart

Malin Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-1.60

-1.50

-0.10

-0.30

Malin Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Change In Receivables	Get a 7-Day Free Trial															1.30	-0.20	0.10	-	-

Malin Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Malin (LTS:0Y71) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Malin's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Malin's accounts receivable are only considered to be worth 75% of book value:

Malin's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	62.1	-	5.3	+	0.75 * 0	+	0.5 * 0
=	56.80

Malin Change In Receivables Related Terms

Thank you for viewing the detailed overview of Malin's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Malin Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Malin Corporation PLC (LTS:0Y71) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

MLC:Ireland

Address

50 Richmond Street South, The Lennox Building, Dublin, IRL, D02 FK02

Website

http://www.malinplc.com

Malin Corporation PLC is a life sciences company. Its investee companies are in science and discovery, clinical and commercial sectors. The company's approach is to create shareholder value through the selective long-term application of capital and operational expertise to private, pre-trade sale operating businesses in the life sciences industry. The company derives all of its revenue from its subsidiary. The company focuses on oncology, immunology, and genetic diseases where it believes that life science and healthcare technologies will deliver transformative treatments for patients.

Malin Headlines

No Headlines